D-0630-2021 Class III Terminated
FDA drug recall D-0630-2021 was initiated by McKesson Corporation Dba McKesson Drug Company on May 26, 2021 and is designated Class III. Reason for recall: Labeling; Wrong Barcode; error in the machine-readable barcode which could result in some units being read as Naproxen Tablets 500 mg. Product is labeled correctly as Levetiracetam The recall status is terminated (terminated Sep 29, 2022). Affected quantity: 210 cartons.
Recall Details
- Product Type
- Drugs
- Report Date
- Jun 16, 2021
- Initiation Date
- May 26, 2021
- Termination Date
- Sep 29, 2022
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 210 cartons
Product Description
Levetiracetam Tablets USP, 250 mg UD 100 Tablets (10x10) boxes, Rx Only, Distributed By: McKesson Corporation 4971 Southridge Blvd., Suite 101 Memphis, TN 38141 Manufactured by: Aurobindo Pharma Limited Hyderabad-500 090, India NDC 63739-795-10
Reason for Recall
Labeling; Wrong Barcode; error in the machine-readable barcode which could result in some units being read as Naproxen Tablets 500 mg. Product is labeled correctly as Levetiracetam
Distribution Pattern
Nationwide in the US
Code Information
Lot: 0000124916 Exp. 09/30/2022
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0630-2021
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026